FDA panel backs Exjade

FDA's Blood Products Advisory Committee voted unanimously to recommend approval of Exjade deferasirox from Novartis (NVS; SWX:NOVN) to treat chronic iron overload due to blood transfusions in patients six years of age or older. The PDUFA date for the once-daily oral iron chelator is at the year end. The NDA was submitted in May and has Priority Review. ...